Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to 'switching' in bipolar disorder?
- PMID: 18982003
- PMCID: PMC2874651
- DOI: 10.1038/mp.2008.117
Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to 'switching' in bipolar disorder?
Abstract
Agents effective against mania in bipolar disorder are reported to decrease turnover of arachidonic acid (AA) in phospholipids and expression of calcium-dependent AA-selective cytosolic phospholipase A(2) (cPLA(2)) in rat brain. In contrast, fluoxetine, an antidepressant that is reported to switch bipolar depressed patients to mania, increases cPLA(2) expression and AA turnover in rat brain. We therefore hypothesized that antidepressants that increase switching to mania generally increase cPLA(2) and AA turnover in brain. To test this hypothesis, adult male CDF-344 rats were administered imipramine and bupropion, with reported high and low switching rates, respectively, at daily doses of 10 and 30 mg kg(-1) i.p., respectively, or i.p. saline (control) for 21 days. Frontal cortex expression of different PLA(2) enzymes and AA turnover rates in brain when the rats were unanesthetized were measured. Compared with chronic saline, chronic imipramine but not bupropion significantly increased cortex cPLA(2) mRNA activity, protein and phosphorylation, expression of the cPLA(2) transcription factor, activator protein-2alpha (AP-2alpha) and AA turnover in phospholipids. Protein levels of secretory phospholipase A(2), calcium-independent phospholipase A(2), cyclooxygenase (COX)-1 and COX-2 were unchanged, and prostaglandin E(2) was unaffected. These results, taken with prior data on chronic fluoxetine in rats, suggest that antidepressants that increase the switching tendency of bipolar depressed patients to mania do so by increasing AA recycling and metabolism in brain. Mania in bipolar disorder thus may involve upregulated brain AA metabolism.
Figures





Similar articles
-
Chronic NMDA administration to rats up-regulates frontal cortex cytosolic phospholipase A2 and its transcription factor, activator protein-2.J Neurochem. 2007 Sep;102(6):1918-1927. doi: 10.1111/j.1471-4159.2007.04648.x. Epub 2007 May 10. J Neurochem. 2007. Retraction in: J Neurochem. 2017 Mar;140(6):979. doi: 10.1111/jnc.13947. PMID: 17550430 Retracted.
-
Chronic fluoxetine increases cytosolic phospholipase A(2) activity and arachidonic acid turnover in brain phospholipids of the unanesthetized rat.Psychopharmacology (Berl). 2007 Jan;190(1):103-15. doi: 10.1007/s00213-006-0582-1. Epub 2006 Nov 9. Psychopharmacology (Berl). 2007. Retraction in: Psychopharmacology (Berl). 2017 Feb;234(3):523. doi: 10.1007/s00213-016-4499-z. PMID: 17093977 Retracted.
-
Chronic fluoxetine upregulates activity, protein and mRNA levels of cytosolic phospholipase A2 in rat frontal cortex.Pharmacogenomics J. 2006 Nov-Dec;6(6):413-20. doi: 10.1038/sj.tpj.6500391. Epub 2006 Apr 25. Pharmacogenomics J. 2006. Retraction in: Pharmacogenomics J. 2017 Dec;17(6):563. doi: 10.1038/tpj.2017.42. PMID: 16636684 Retracted.
-
Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade.ACS Chem Neurosci. 2014 Jun 18;5(6):459-67. doi: 10.1021/cn500058v. Epub 2014 May 15. ACS Chem Neurosci. 2014. PMID: 24786695 Free PMC article. Review.
-
Bipolar disorder and mechanisms of action of mood stabilizers.Brain Res Rev. 2009 Oct;61(2):185-209. doi: 10.1016/j.brainresrev.2009.06.003. Epub 2009 Jun 23. Brain Res Rev. 2009. PMID: 19555719 Free PMC article. Review.
Cited by
-
Molecular pharmacology in a simple model system: implicating MAP kinase and phosphoinositide signalling in bipolar disorder.Semin Cell Dev Biol. 2011 Feb;22(1):105-13. doi: 10.1016/j.semcdb.2010.11.002. Epub 2010 Nov 18. Semin Cell Dev Biol. 2011. PMID: 21093602 Free PMC article. Review.
-
Association of plasma ω-3 and ω-6 lipids with burden of disease measures in bipolar subjects.J Psychiatr Res. 2012 Nov;46(11):1435-41. doi: 10.1016/j.jpsychires.2012.07.016. Epub 2012 Aug 11. J Psychiatr Res. 2012. PMID: 22884424 Free PMC article.
-
Are Polyunsaturated Fatty Acids Implicated in Histaminergic Dysregulation in Bipolar Disorder?: AN HYPOTHESIS.Front Physiol. 2018 Jun 12;9:693. doi: 10.3389/fphys.2018.00693. eCollection 2018. Front Physiol. 2018. PMID: 29946266 Free PMC article. Review.
-
Adjunctive dietary intervention for bipolar disorder: a randomized, controlled, parallel-group, modified double-blinded trial of a high n-3 plus low n-6 diet.Bipolar Disord. 2022 Mar;24(2):171-184. doi: 10.1111/bdi.13112. Epub 2021 Aug 2. Bipolar Disord. 2022. PMID: 34218509 Free PMC article. Clinical Trial.
-
Polyunsaturated fatty acid associations with dopaminergic indices in major depressive disorder.Int J Neuropsychopharmacol. 2014 Mar;17(3):383-91. doi: 10.1017/S1461145713001399. Epub 2013 Dec 3. Int J Neuropsychopharmacol. 2014. PMID: 24300434 Free PMC article.
References
-
- Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60:261–269. - PubMed
-
- Boerlin HL, Gitlin MJ, Zoellner LA, Hammen CL. Bipolar depression and antidepressant-induced mania: a naturalistic study. J Clin Psychiatry. 1998;59:374–379. - PubMed
-
- Settle EC, Jr, Settle GP. A case of mania associated with fluoxetine. Am J Psychiatry. 1984;141:280–281. - PubMed
-
- Rao JS, Lee HJ, Rapoport SI, Bazinet RP. Mode of action of mood stabilizers: is the arachidonic acid cascade a common target? Mol Psychiatry. 2008;13:585–596. - PubMed
-
- Lucas KK, Dennis EA. Distinguishing phospholipase A2 types in biological samples by employing group-specific assays in the presence of inhibitors. Prostaglandins Other Lipid Mediat. 2005;77:235–248. - PubMed